Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

46.16 +2.20 (+5.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,734,986
Open 44.54
Bid (Size) 45.00 (200)
Ask (Size) 47.00 (200)
Prev. Close 43.96
Today's Range 44.54 - 46.56
52wk Range 28.66 - 91.00
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener... 
Via StockStory
Topics Economy
News headline image
Deadline Soon: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire

Performance

YTD
+20.8%
+20.8%
1 Month
+38.6%
+38.6%
3 Month
+32.9%
+32.9%
6 Month
-41.3%
-41.3%
1 Year
-25.8%
-25.8%

More News

Read More
News headline image
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
From SkyMedia, LLC
Via GlobeNewswire
Corcept Therapeutics Inc (NASDAQ:CORT): An Affordable Growth Stock Built on a Strong Foundation ↗
Via Chartmill
News headline image
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
3 Overrated Stocks That Concern Us
Via StockStory
News headline image
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
CORT SHAREHOLDER ACTION ALERT: Kaplan Fox Alerts Investors of a Class Action Lawsuit Against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Lead Plaintiff Deadline on April 21, 2026
Via TheNewswire.com
Topics Lawsuit
News headline image
CORT SHAREHOLDER ACTION ALERT: Kaplan Fox Alerts Investors of a Class Action Lawsuit Against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Lead Plaintiff Deadline on April 21, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
DEADLINE ALERT: Kaplan Fox Alerts Investors to a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Deadline is April 21, 2026
Via TheNewswire.com
Topics Lawsuit
News headline image
DEADLINE ALERT: Kaplan Fox Alerts Investors to a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Deadline is April 21, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
Securities Class Action Deadline Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Contact Kaplan Fox Before April 21, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
Securities Class Action Deadline Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Contact Kaplan Fox Before April 21, 2026
Via TheNewswire.com
Topics Lawsuit
News headline image
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds
Via StockStory
News headline image
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
From SkyMedia, LLC
Via GlobeNewswire
News headline image
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
CORT DEADLINE ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Lead Plaintiff Deadline on April 21, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
CORT DEADLINE ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Lead Plaintiff Deadline on April 21, 2026
Via TheNewswire.com
Topics Lawsuit
News headline image
CORT INVESTOR ALERT: Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) Are Encouraged to Contact Kaplan Fox Before Lead Plaintiff Deadline on April 21, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
CORT INVESTOR ALERT: Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) Are Encouraged to Contact Kaplan Fox Before Lead Plaintiff Deadline on April 21, 2026
Via TheNewswire.com
Topics Lawsuit
News headline image
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
What is the current price of Corcept Therapeutics Incorporated - Common Stock?
The current price of Corcept Therapeutics Incorporated - Common Stock is 46.16
When was Corcept Therapeutics Incorporated - Common Stock last traded?
The last trade of Corcept Therapeutics Incorporated - Common Stock was at 04/17/26 04:00 PM ET
What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 5.35B
How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
Corcept Therapeutics Incorporated - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.